current uses and outcomes of hematopoietic stem cell transplantation 2013
DESCRIPTION
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013. Location of Centers Participating in the CIBMTR 2013. Transplant Activity in the US. Allogeneic Stem Cell Sources by Recipient Age. Autologous Stem Cell Sources by Recipient Age. - PowerPoint PPT PresentationTRANSCRIPT
Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2013
Location of Centers Participatingin the CIBMTR 2013
Transplant Activity in the US
Allogeneic Stem Cell Sources by Recipient Age
Autologous Stem Cell Sources by Recipient Age
Trends in Transplantsby Type and Recipient Age*
Trends in Transplants by Transplant Type and Recipient Age*
Indications for Hematopoietic Stem Cell Transplants in the US, 2011
Indications for Hematopoietic Stem Cell Transplants for Age ≤ 20 years, in the US, 2011
Allogeneic Transplants for Age ≤ 20 years, Registered with the CIBMTR
Allogeneic Transplants for Age > 20 years, Registered with the CIBMTR
Unrelated Donor Stem Cell Sourcesby Recipient Age
Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR
One-year Survival by Year of Transplant, Donor and Age, Worldwide
100-day Mortality after Autologous Transplants, 2010-2011
100-day Mortality after HLA-identical Sibling Transplants, 2010-2011
100-day Mortality after Unrelated Donor Transplants, 2010-2011
Causes of Death after Autologous Transplants done in 2010-2011
Causes of Death after HLA-identical Sibling Transplants done in 2010-2011
Causes of Death after Unrelated Donor Transplants done in 2010-2011
Allogeneic Transplants Registered with the CIBMTR
Allogeneic Transplants after Reduced Intensity Conditioning, by Donor Type, Registered with CIBMTR
Proportion of Allogeneic Transplants with Reduced Intensity Conditioning for Different Indications
Survival after HLA-identical Sibling Donor Transplants for AML, 2001-2011
Survival after Unrelated Donor Transplants for AML, 2001-2011
Survival after HLA-identical Sibling Donor Transplants for AML, Age < 20 years, 2001-2011
Survival after Allogeneic Transplants for MDS, 2001-2011
Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 years, 2001-2011
Survival after Unrelated Donor Transplants for ALL, Age < 20 years, 2001-2011
Survival after HLA-identical Sibling Donor Transplants for ALL, Age ≥ 20 years, 2001-2011
Survival after Unrelated Donor Transplants for ALL, Age ≥ 20 Years, 2001-2011
Survival after HLA-identical Sibling Donor Transplants for CML, 2001-2011
Survival after HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL,
2001-2011
Survival after Allogeneic Transplants for SAA, 2001-2011
Survival after Autologous Transplants for Hodgkin Lymphoma, 2001-2011
Survival after Allogeneic Transplants for Hodgkin Lymphoma, 2001-2011
Survival after Autologous Transplants for Follicular Lymphoma, 2001-2011
Survival after Allogeneic and HLA-identical Sibling Transplants for Follicular Lymphoma, 2001-2011
Survival after Autologous Transplants for Diffuse Large B-Cell Lymphoma, 2001-2010
Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell Lymphoma, 2001-2011
Survival after Transplants for Mantle Cell Lymphoma, 2001-2011
Survival after Transplants for Multiple Myeloma, 2001-2011